ACST Acasti Pharma
- 2.6900
- -0.0699-2.53%
Acasti Pharma News
Acasti Pharma (ACST) Gets a Buy From Craig-Hallum
Acasti Pharma Q3 EPS $(0.21) Up From $(0.52) YoY
Acasti Pharma (NASDAQ:ACST) reported quarterly losses of $(0.21) per share. This is a 59.62 percent increase over losses of $(0.52) per share from the same period last year.
Acasti Pharma 3Q Loss/Shr 21c >ACST
Acasti Pharma 3Q Loss/Shr 21c >ACST
Acasti Pharma: Projected Cash Runway Extends Into Second Calendar Qtr 2026 >ACST
Acasti Pharma: Projected Cash Runway Extends Into Second Calendar Qtr 2026 >ACST
Acasti Pharma: Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, on Track for NDA Submission Timeline >ACST
Acasti Pharma: Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, on Track for NDA Submission Timeline >ACST
Acasti Pharma Initiated at Buy by Craig-Hallum
Acasti Pharma Initiated at Buy by Craig-Hallum
Craig-Hallum Initiates Coverage On Acasti Pharma With Buy Rating, Announces Price Target of $6
Craig-Hallum analyst Chase Knickerbocker initiates coverage on Acasti Pharma (NASDAQ:ACST) with a Buy rating and announces Price Target of $6.
Acasti Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/07/2024 130.77% Craig-Hallum → $6 Initiates Coverage On → Buy 02/15/2023 -3.85% EF Hutton → $2.5 Reiter
Acasti Announces Poster Detailing Its GTX-104 STRIVE-ON Trial
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of
Acasti Pharma GAAP EPS of -$0.43
Acasti Pharma Cash and Cash Equivalents as of Sept 30 Totaled $27M >ACST
Acasti Pharma Cash and Cash Equivalents as of Sept 30 Totaled $27M >ACST
Acasti Pharma 2Q Loss/Shr 43c >ACST
Acasti Pharma 2Q Loss/Shr 43c >ACST
Press Release: Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights -- Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 -- Completed
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well
Aker BioMarine Gains Krill Assets From Acasti Pharma in $3.1 Million Settlement Deal
Aker BioMarine (AKBM.OL) said Tuesday it acquired certain assets from late-stage specialty pharma company Acasti Pharma as part of the latter's contractual settlement of $3.1 million to the group. The
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
With achievement of enrollment milestone, pivotal STRIVE-ON safety trial on track for potential NDA submission anticipated to occur in the first half of calendar 2025 Recently announced $7.5 million p
Analysts Offer Insights on Healthcare Companies: Acasti Pharma (ACST), Omnicell (OMCL) and MoonLake Immunotherapeutics (MLTX)
Optimistic Outlook for Acasti Pharma's GTX-104: Assessing Buy Rating and Potential Impact on Aneurysmal Subarachnoid Hemorrhage Treatment
Analysis
Price Target
No Data
